Q2 EPS Forecast for Gain Therapeutics Lifted by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Equities researchers at HC Wainwright boosted their Q2 2025 earnings per share estimates for Gain Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.16) per share for the quarter, up from their prior forecast of ($0.19). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Gain Therapeutics' current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Gain Therapeutics' Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.59) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.56) EPS.

Several other brokerages also recently weighed in on GANX. Chardan Capital restated a "buy" rating and set a $6.00 target price on shares of Gain Therapeutics in a research note on Friday, March 28th. Scotiabank began coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 target price on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Gain Therapeutics currently has a consensus rating of "Buy" and an average price target of $8.20.

Gain Therapeutics Stock Performance

GANX stock traded up $0.01 during mid-day trading on Wednesday, reaching $1.80. 72,466 shares of the stock traded hands, compared to its average volume of 311,633. The firm has a market capitalization of $53.20 million, a PE ratio of -1.64 and a beta of 0.17. The business has a 50-day moving average of $1.90 and a two-hundred day moving average of $1.99. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $3.19. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sprott Inc. bought a new stake in Gain Therapeutics in the 4th quarter valued at $30,000. Benedict Financial Advisors Inc. bought a new stake in Gain Therapeutics in the fourth quarter valued at about $35,000. Bridgeway Capital Management LLC acquired a new position in Gain Therapeutics in the fourth quarter worth about $65,000. Kovitz Investment Group Partners LLC bought a new position in Gain Therapeutics during the first quarter worth about $91,000. Finally, Northern Trust Corp lifted its stake in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after purchasing an additional 39,642 shares during the period. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.